Dr Reddy’s receives USFDA approval to launch Desloratadine ODT

25 Jan 2013 Evaluate

Dr Reddy’s Laboratories has launched Desloratadine Orally Disintegrating Tablets (ODT) (2.5 mg & 5 mg), a bioequivalent generic version of Clarinex Reditabs (desloratadine) in the US market on January 24, 2013. Dr Reddy’s ANDA for Desloratadine ODT is approved by the United States Food & Drug Administration (USFDA). The company’s Desloratadine ODT 2.5 mg & 5 mg are available in unit dose packages of 30 (5x6).

The Clarinex Reditabs brand had US sales of approximately $5.3 million for the most recent twelve months ending November 2012 according to IMS Health.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1235.15 18.00 (1.48%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×